Melbourne, 30 June 2026
CSL Seqirus, part of leading Australian biotechnology company CSL, has today welcomed the news that neffy® adrenaline (epinephrine) nasal spray will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 July 2026, improving access for eligible Australians at risk of anaphylaxis. neffy is reimbursed for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over.1
Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline. 2
Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure and should be given without delay.2
Anaphylaxis rates have increased over recent decades.3
Australia has one of the highest documented rates of anaphylaxis hospital admissions in the developed world.4 Between 2015 and 2020, Australian public hospitals reported a 51% increase in emergency department presentations and a 35% increase in hospitalisations due to anaphylaxis.5,6
According to Professor Connie Katelaris AM, leading NSW allergist, the reimbursement of neffy is an important development for Australians who are at risk of anaphylaxis.
"Previously only available as private prescription, PBS listing of neffy gives more Australian patients the ability to access neffy should this be their preferred adrenaline device for the emergency treatment of anaphylaxis," says Professor Katelaris.
"Anaphylaxis is a difficult condition to manage and the availability of subsidised adrenaline options means Australians living with anaphylaxis and their doctors have more choice in treatment options."
Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, says living with the risk of anaphylaxis can have a significant impact on the daily lives of Australians.
"For people who are at risk of anaphylaxis, everyday activities that many Australians take for granted often require careful planning and constant vigilance. Whether it's eating at restaurants, attending social events or travelling, those living with the risk of anaphylaxis are frequently thinking ahead about how to stay safe and what they would do in an emergency.
"For parents and carers of children at risk of anaphylaxis, experiences such as play dates, parties and school excursions require additional planning and preparation," says Ms Said.
"People living with severe allergies know that there is no one-size-fits-all approach to managing anaphylaxis. The reimbursement of a treatment option that does not require injection provides patients with more choice to determine what may work best for them."
Associate Professor Kristina Rueter, Anaphylaxis Committee Chair of the Australasian Society of Clinical Immunology and Allergy (ASCIA), says healthcare professionals are being supported through updated clinical guidance and educational resources that now include neffy.
"ASCIA has updated its anaphylaxis guidelines, training modules and resources to include neffy, ensuring healthcare professionals have access to current information on available treatment options for anaphylaxis," said Professor Rueter.
"Developed in consultation with allergy specialists and healthcare professionals, these updates aim to meaningfully support clinicians with practical, evidence-based resources around the management and treatment of anaphylaxis."
Claire Morgan, Senior Medical Director of Pharmaceuticals at CSL Seqirus, says the PBS listing is an important milestone in improving access and choice for Australians at risk of anaphylaxis.
"At CSL Seqirus, we are committed to improving access to medicines for Australian patients, and the PBS listing of this treatment option is an important milestone for people at risk of anaphylaxis," says Ms Morgan.
"We are pleased that eligible Australians will now have subsidised access to this treatment option and acknowledge the valuable contribution of healthcare professionals, patient advocacy organisations and professional bodies in supporting the allergy community."
About neffy
neffy should be used at any signs or symptoms of anaphylaxis. After using adrenaline patients should seek emergency medical assistance immediately for close monitoring and in the event further treatment is required. neffy should not be withheld from anyone who is considered to need it. Anaphylaxis treatment options and management should be discussed with a patient's clinician. neffy is a registered prescription medicine and can only prescribed by a doctor.
Side effects:7 All medicines can have side effects. Common side effects reported following neffy include headache, nasal discomfort, throat irritation and feeling jittery.
